Salvat, Arbor launch OTOVEL otic solution

Laboratorios Salvat S.A.and Arbor Pharmaceuticals LLC recently partnered on the launch of OTOVEL (ciprofloxacin 0.3% and fluocinolone acetonide 0.025%) otic solution.

OTOVEL is the first and, currently, the only ear drop that combines of antibiotics and steroids that is available in a sterile, single unit-dose package that is free of preservatives.

"We are very pleased to be partnering with Salvat to represent OTOVEL in the U.S.," Arbor President and CEO Ed Schutter said. "OTOVEL is a perfect fit with our other pediatric products that are sold by our team of over 200 sales professionals throughout the country."

Salvat owns the rights to OTOVEL, which will be distributed exclusively by Arbor in the United States.

"It is exciting to further expand the international commercial availability of OTOVEL through the partnership with Arbor in the U.S." Salvat CEO Alberto Bueno said. "This new launch of OTOVEL is a major milestone for Salvat as we continue to grow our presence in the U.S. market."